These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804 [TBL] [Abstract][Full Text] [Related]
5. Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation. Prescrire Int; 2002 Dec; 11(62):177-8. PubMed ID: 12469696 [TBL] [Abstract][Full Text] [Related]
6. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
7. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
8. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Geller DE; Rosenfeld M; Waltz DA; Wilmott RW; Chest; 2003 Jan; 123(1):28-36. PubMed ID: 12527599 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
12. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180 [TBL] [Abstract][Full Text] [Related]
13. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647 [TBL] [Abstract][Full Text] [Related]
14. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Coates AL; Green M; Leung K; Chan J; Ribeiro N; Louca E; Ratjen F; Charron M; Tservistas M; Keller M Pediatr Pulmonol; 2008 Aug; 43(8):753-9. PubMed ID: 18613006 [TBL] [Abstract][Full Text] [Related]
15. ABT-773 (Abbott Laboratories). Lawrence LE Curr Opin Investig Drugs; 2001 Jun; 2(6):766-72. PubMed ID: 11572654 [TBL] [Abstract][Full Text] [Related]
16. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Nikolaizik WH; Trociewicz K; Ratjen F Eur Respir J; 2002 Jul; 20(1):122-6. PubMed ID: 12166559 [TBL] [Abstract][Full Text] [Related]
17. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Mouton JW; Jacobs N; Tiddens H; Horrevorts AM Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500 [TBL] [Abstract][Full Text] [Related]
19. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Halwani M; Blomme S; Suntres ZE; Alipour M; Azghani AO; Kumar A; Omri A Int J Pharm; 2008 Jun; 358(1-2):278-84. PubMed ID: 18448284 [TBL] [Abstract][Full Text] [Related]
20. Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review. Vandevanter DR; Geller DE Med Devices (Auckl); 2011; 4():179-88. PubMed ID: 22915944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]